ADMA Biologics Inc (ADMA) - Total Assets
Based on the latest financial reports, ADMA Biologics Inc (ADMA) holds total assets worth $624.24 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of ADMA Biologics Inc for net asset value and shareholders' equity analysis.
ADMA Biologics Inc - Total Assets Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's total assets have evolved over time, based on quarterly financial data.
ADMA Biologics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ADMA Biologics Inc's total assets of $624.24 Million consist of 74.7% current assets and 25.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.0% |
| Accounts Receivable | $158.43 Million | 25.4% |
| Inventory | $206.47 Million | 33.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $632.00K | 0.1% |
| Goodwill | $3.53 Million | 0.6% |
Asset Composition Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ADMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ADMA Biologics Inc's current assets represent 74.7% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, down from 100.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 33.1% of total assets.
ADMA Biologics Inc Competitors by Total Assets
Key competitors of ADMA Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
ADMA Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.71 | 5.97 | 8.36 |
| Quick Ratio | 3.74 | 2.90 | 3.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $396.97 Million | $275.87 Million | $156.07 Million |
ADMA Biologics Inc - Advanced Valuation Insights
This section examines the relationship between ADMA Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.48 |
| Latest Market Cap to Assets Ratio | 4.01 |
| Asset Growth Rate (YoY) | 27.7% |
| Total Assets | $624.24 Million |
| Market Capitalization | $2.51 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values ADMA Biologics Inc's assets at a significant premium (4.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ADMA Biologics Inc's assets grew by 27.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ADMA Biologics Inc (2006–2025)
The table below shows the annual total assets of ADMA Biologics Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $624.24 Million | +27.74% |
| 2024-12-31 | $488.68 Million | +48.45% |
| 2023-12-31 | $329.18 Million | -5.53% |
| 2022-12-31 | $348.46 Million | +26.14% |
| 2021-12-31 | $276.25 Million | +33.02% |
| 2020-12-31 | $207.67 Million | +63.41% |
| 2019-12-31 | $127.09 Million | +43.00% |
| 2018-12-31 | $88.88 Million | -17.72% |
| 2017-12-31 | $108.02 Million | +356.06% |
| 2016-12-31 | $23.69 Million | -0.12% |
| 2015-12-31 | $23.71 Million | -12.90% |
| 2014-12-31 | $27.23 Million | -14.86% |
| 2013-12-31 | $31.98 Million | +105.59% |
| 2012-12-31 | $15.56 Million | +192441.39% |
| 2011-12-31 | $8.08K | -32.74% |
| 2010-12-31 | $12.01K | -99.86% |
| 2009-12-31 | $8.69 Million | +228.22% |
| 2008-12-31 | $2.65 Million | -81.93% |
| 2007-12-31 | $14.65 Million | 0.00% |
| 2006-12-31 | $14.65 Million | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more